Perfuze

Advancing stroke treatment:
Innovative catheter technology designed for efficient vessel access, with better potential for complete clot ingestion.

[Society of NeuroInterventional Surgery (SNIS) @SNISinfo]

Join speakers David Fiorella, MD, @SunilAShethMD
& moderator Tarun Bhalla, MD for “Corrugated by Design: How Next-Generation Aspiration Technology is Redefining First-Pass Success in Stroke” 5/4 at 4PM ET. Thank you to @PerfuzeStroke for sharing this webinar with our members.

[Perfuze @PerfuzeStroke]

The first case with our Millipede88 Aspiration Catheter after 510(k) clearance was performed in Texas: TICI 3 reperfusion. Dr. Sunil Sheth zipped to the clot with the Zipline88 and smoothly delivered the Millipede88 for efficient thrombectomy.
#StrokeCare #Millipede88 #Perfuze

[Perfuze @PerfuzeStroke]

FDA cleared. A defining moment for Perfuze and for stroke care. Backed by record MARRS data: 77% first-pass effect and 96% deliverability in an independently adjudicated study.

🔗 Full announcement: https://t.co/VORNC0IFwt

#MedTech #StrokeCare #FDACleared #Perfuze #Millipede88

[Perfuze @PerfuzeStroke]

2025 in a snapshot. Thank you for being part of the journey.

A special welcome to our new VPs, Joe Rotger, Paul Maguire, and Ibrahim Ali, who joined us this year.

Happy Holidays and here’s to a fantastic start to 2026!

[Perfuze @PerfuzeStroke]

TICI 3 reperfusion in a single pass.

Dr. Demetrius Lopes (@Cure4Stroke) zipped to the clot with the Zipline™ 70 Access Catheter and smoothly delivered the Millipede™ 70 for efficient thrombectomy.
#ZipToTheClot #Zipline70 #Millipede70 #StrokeCare #Neurovascular #Perfuze

[Perfuze @PerfuzeStroke]

The #Perfuze Team is growing and we're excited to welcome our latest additon, Mike Abbruzzese! Mike will be managing our commercial expansion efforts in the New York region. His experience and passion for advancing Stroke Care make him a great addition to our growing team.

[Perfuze @PerfuzeStroke]

We are hiring! We’re excited to begin recruitment for a Midwest Territory Manager as we continue expanding our U.S. commercial team.

Apply now:

📍 Chicago: https://t.co/1A9xZiaiUp
📍 Detroit: https://t.co/Mcw6ruB4dv

#MedTechJobs #Hiring

[Perfuze @PerfuzeStroke]

We are hiring! As we expand our U.S. team, we are looking for a Clinical Specialist in the Texas market, to join our U.S. commercial team.

Learn more and apply here: https://t.co/ms61v5ovGP

#Hiring #MedTech

@Wayne_Perfuze

[Perfuze @PerfuzeStroke]

As we expand into the US market, we are pleased to welcome our newest team member, Thomas Patterson, who is joining the Perfuze Sales Team. Welcome to the team, Thomas! We’re excited for what’s ahead.

@Wayne_Perfuze

#NewTeamMember #MedTech #Perfuze

[Perfuze @PerfuzeStroke]

We’re delighted to welcome Ibrahim Ali as our new VP of Marketing at Perfuze. Ibrahim brings deep expertise and proven leadership in the neurovascular and broader medical device space, and will play a pivotal role in advancing Perfuze’s global growth and impact.
@Wayne_Perfuze

[Perfuze @PerfuzeStroke]

As we expand into the US market, we are pleased to welcome our newest team member, Lisa Fallon, who is joining the Perfuze Sales Team.

Welcome to the team, Lisa! We’re excited for what’s ahead.

@Wayne_Perfuze #NewTeamMember #MedTech #Perfuze

[Perfuze @PerfuzeStroke]

Join our CEO, @Wayne_Perfuze, tomorrow, September 10, at 10:40 am (GMT), at @lsintelligence Europe ‘25, as he unveils what’s ahead for Perfuze: from expanding in the U.S. market to advancing stroke care with the Millipede System.

#LSIEurope #NeuroIntervention #Perfuze

[Perfuze @PerfuzeStroke]

We are thrilled to announce that our CEO, @Wayne_Perfuze, will be joining the panel discussion “An Irish Advantage: A Hub for International Growth” at @lsintelligence Europe ‘25, tomorrow, September 9, at 3:45 pm (GMT).

#LSIEurope #IrishInnovation #NeuroIntervention #Perfuze

[Perfuze @PerfuzeStroke]

"In stroke thrombectomy, device performance can be the difference between long-term disability and full recovery”, said Liam Mullins, CTO at Perfuze.

Watch him explain the reasons behind our excellent preliminary MARRS trial results. * Per Protocol Population

@Wayne_Perfuze

[Perfuze @PerfuzeStroke]

We recently joined forces with @CroiHeartStroke – a #Galway-based charity dedicated to heart and stroke prevention and recovery. Our team took on a step challenge to support the fundraising.

We were thrilled to have @Mcubbard present the cheque to Croí on behalf of #Perfuze.

[Perfuze @PerfuzeStroke]

We've been selected to present at @lsintelligence Europe ’25 in #London.

Join us as our CEO, @Wayne_Perfuze, takes the stage to outline future funding plans, and provide insights into the Millipede System, our innovative approach to improving ischemic stroke treatment.

[Perfuze @PerfuzeStroke]

Preliminary results from the MARRS pivotal IDE trial were presented at @SNISinfo, highlighting Millipede88 performance in acute ischemic stroke:
🔹 77% First Pass Effect for M1 occlusions
🔹 99% Delivery success
🔹 Promising safety profile

https://t.co/GXSU8PJ9dF

@Wayne_Perfuze

[Perfuze @PerfuzeStroke]

TODAY, at 11:10 AM CDT during Late-Breaking session, our preliminary data of the MARRS study will be presented by Dr. Raul Nogueira, MD!

Stay tuned.

@SNISinfo, @Wayne_Perfuze

[Perfuze @PerfuzeStroke]

We are sharing our preliminary data publicly for the first time at @SNISinfo 2025 Annual Meeting in Nashville on 16 July, during Late-Breaking session at 11:10 AM CDT.

See you there.

@Wayne_Perfuze

#SNIS2025 #MARRSStudy #Millipede088 #Perfuze

[Perfuze @PerfuzeStroke]

Meet us at the @SNISinfo 2025 Annual Meeting in Nashville – we'll be at Booth No 302.

cc: @Wayne_Perfuze

#SNIS2025 #MARRSStudy #Millipede088 #Perfuze

[Perfuze @PerfuzeStroke]

We are sharing our preliminary data publicly for the first time at @SNISinfo 2025 Annual Meeting in Nashville on 16 July, during Late-Breaking session at 11:10 AM CDT.

See you there.

@Wayne_Perfuze

#SNIS2025 #MARRSStudy #Millipede088 #Perfuze